
Arya News - The Binnopharm pharmaceutical plant in Moscow’s Zelenograd district has produced more than 32.4 million canisters of aerosol medication for respiratory diseases since 2021.
The plant, part of the Binnopharm Group, produced more than 2.5 million packs in the first 10 months of 2026 alone, according to Anatoly Garbuzov, a Moscow city government minister and head of the city’s Department of Investment and Industrial Policy.Binnopharm’s aerosol medications are on Russia’s list of vital and essential medicines. They are used to treat chronic obstructive pulmonary disease (COPD), asthma, bronchitis, and other respiratory conditions.The plant uses quality checks at every stage of production to ensure that each dose is safe and effective. Staff follow precise formulations, fill and seal the pressurized canisters, and run laboratory tests on intermediate and finished products to meet international quality standards. Production teams include manufacturing technologists, analytical chemists, engineers, line operators, and quality control specialists.Binnopharm is investing in its manufacturing operations with support from the city. Its designation as an industrial complex makes it eligible for tax breaks.